Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger and R. Mechoulam: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949 (1992)

  • [2]V. Ralevic and D. A. Kendall: Cannabinoid modulation of perivascular sympathetic and sensory neurotransmission. Curr Vasc Pharmacol, 7, 15-25 (2009)

  • [3]F. J. Bermudez-Silva, M. P. Viveros, J. M. McPartland and F. Rodriguez de Fonseca: The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav, 95, 375-382 (2010)

  • [4]C. Turcotte, F. Chouinard, J. S. Lefebvre and N. Flamand: Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol, 97, 1049-1070 (2015)

  • [5]J. Z. Long, M. LaCava, X. Jin and B. F. Cravatt: An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res, 52, 337-344 (2011)

  • [6]D. G. Deutsch, M. S. Goligorsky, P. C. Schmid, R. J. Krebsbach, H. H. Schmid, S. K. Das, S. K. Dey, G. Arreaza, C. Thorup, G. Stefano and L. C. Moore: Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest, 100, 1538-1546 (1997)

  • [7]J. K. Ritter, C. Li, M. Xia, J. L. Poklis, A. H. Lichtman, R. A. Abdullah, W. L. Dewey and P. L. Li: Production and actions of the anandamide metabolite prostamide E2 in the renal medulla. J Pharmacol Exp Ther, 342, 770-779 (2012)

  • [8]E. J. Johns, U. C. Kopp and G. F. DiBona: Neural control of renal function. Compr Physiol, 1, 731-767 (2011)

  • [9]S. A. Gaskari, H. Liu, C. D’Mello, G. Kunos and S. S. Lee: Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol, 62, 1272-1277 (2015)

  • [10]C. Maric, P. J. Harris and D. Alcorn: Changes in mean arterial pressure predict degranulation of renomedullary interstitial cells. Clin Exp Pharmacol Physiol, 29, 1055-1059 (2002)

  • [11]H. Cadas, S. Gaillet, M. Beltramo, L. Venance and D. Piomelli: Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci, 16, 3934-3942 (1996)

  • [12]X. H. Jin, Y. Okamoto, J. Morishita, K. Tsuboi, T. Tonai and N. Ueda: Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J Biol Chem, 282, 3614-3623 (2007)

  • [13]J. Liu, L. Wang, J. Harvey-White, D. Osei-Hyiaman, R. Razdan, Q. Gong, A. C. Chan, Z. Zhou, B. X. Huang, H. Y. Kim and G. Kunos: A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A, 103, 13345-13350 (2006)

  • [14]Y. Okamoto, K. Tsuboi and N. Ueda: Enzymatic formation of anandamide. Vitam Horm, 81, 1-24 (2009)

  • [15]Y. X. Sun, K. Tsuboi, Y. Okamoto, T. Tonai, M. Murakami, I. Kudo and N. Ueda: Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J, 380, 749-756 (2004)

  • [16]N. Ohshima, T. Kudo, Y. Yamashita, S. Mariggiò, M. Araki, A. Honda, T. Nagano, C. Isaji, N. Kato, D. Corda, T. Izumi and N. Yanaka: New members of the mammalian glycerophosphodiester phosphodiesterase family: GDE4 and GDE7 produce lysophosphatidic acid by lysophospholipase D activity. J Biol Chem, 290, 4260-4271 (2015)

  • [17]K. Tsuboi, Y. Okamoto, I. A. Rahman, T. Uyama, T. Inoue, A. Tokumura and N. Ueda: Glycerophosphodiesterase GDE4 as a novel lysophospholipase D: a possible involvement in bioactive N-acylethanolamine biosynthesis. Biochim Biophys Acta, 1851, 537-548 (2015)

  • [18]D. K. Giang and B. F. Cravatt: Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A, 94, 2238-2242 (1997)

  • [19]B. Q. Wei, T. S. Mikkelsen, M. K. McKinney, E. S. Lander and B. F. Cravatt: A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem, 281, 36569-36578 (2006)

  • [20]B. F. Cravatt, K. Demarest, M. P. Patricelli, M. H. Bracey, D. K. Giang, B. R. Martin and A. H. Lichtman: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A, 98, 9371-9376 (2001)

  • [21]M. D. Breyer and R. C. Harris: Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens, 10, 89-98 (2001)

  • [22]R. C. Harris, J. A. McKanna, Y. Akai, H. R. Jacobson, R. N. Dubois and M. D. Breyer: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest, 94, 2504-2510 (1994)

  • [23]M. Yu, D. Ives and C. S. Ramesha: Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem, 272, 21181-21186 (1997)

  • [24]K. R. Kozak, J. J. Prusakiewicz, S. W. Rowlinson, D. R. Prudhomme and L. J. Marnett: Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry, 42, 9041-9049 (2003)

  • [25]A. Weber, J. Ni, K. H. Ling, A. Acheampong, D. D. Tang-Liu, R. Burk, B. F. Cravatt and D. Woodward: Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res, 45, 757-763 (2004)

  • [26]N. Ueda, K. Yamamoto, S. Yamamoto, T. Tokunaga, E. Shirakawa, H. Shinkai, M. Ogawa, T. Sato, I. Kudo and K. Inoue: Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta, 1254, 127-134 (1995)

  • [27]D. González-Núñez, M. Solé, R. Natarajan and E. Poch: 12-Lipoxygenase metabolism in mouse distal convoluted tubule cells. Kidney Int, 67, 178-186 (2005)

  • [28]A. Gohara, N. Eltaki, D. Sabry, D. Murtagh, J. Jankun, S. H. Selman and E. Skrzypczak-Jankun: Human 5-, 12-and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer. Oncol Rep, 28, 1275-1282 (2012)

  • [29]N. T. Snider, A. M. Kornilov, U. M. Kent and P. F. Hollenberg: Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther, 321, 590-597 (2007)

  • [30]C. Sridar, N. T. Snider and P. F. Hollenberg: Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos, 39, 782-788 (2011)

  • [31]N. T. Snider, M. J. Sikora, C. Sridar, T. J. Feuerstein, J. M. Rae and P. F. Hollenberg: The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther, 327, 538-545 (2008)

  • [32]K. A. Willoughby, S. F. Moore, B. R. Martin and E. F. Ellis: The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther, 282, 243-247 (1997)

  • [33]J. Fu, G. Bottegoni, O. Sasso, R. Bertorelli, W. Rocchia, M. Masetti, A. Guijarro, A. Lodola, A. Armirotti, G. Garau, T. Bandiera, A. Reggiani, M. Mor, A. Cavalli and D. Piomelli: A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci, 15, 64-69 (2012)

  • [34]G. Larrinaga, A. Varona, I. Pérez, B. Sanz, A. Ugalde, M. L. Cándenas, F. M. Pinto, J. Gil and J. I. López: Expression of cannabinoid receptors in human kidney. Histol Histopathol, 25, 1133-1138 (2010)

  • [35]J. C. Lim, S. K. Lim, M. J. Park, G. Y. Kim, H. J. Han and S. H. Park: Cannabinoid receptor 1 mediates high glucose-induced apoptosis via endoplasmic reticulum stress in primary cultured rat mesangial cells. Am J Physiol Renal Physiol, 301, F179-F188 (2011)

  • [36]S. K. Lim and S. H. Park: The high glucose-induced stimulation of B1R and B2R expression via CB(1)R activation is involved in rat podocyte apoptosis. Life Sci, 91, 895-906 (2012)

  • [37]J. C. Lim, S. K. Lim, H. J. Han and S. H. Park: Cannabinoid receptor 1 mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells. J Cell Physiol, 225, 654-663 (2010)

  • [38]L. S. Sampaio, R. Taveira da Silva, D. Lima, C. L. Sampaio, F. A. Iannotti, E. Mazzarella, V. Di Marzo, A. Vieyra, R. A. Reis and M. Einicker-Lamas: The Endocannabinoid System in Renal Cell: Regulation of Na+ Transport by CB1 Receptors Through Distinct Cell Signaling Pathways. Br J Pharmacol, 172, 4615-4625 (2015)

  • [39]G. B. Silva, D. K. Atchison, L. I. Juncos and N. H. García: Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors. Am J Physiol Renal Physiol, 304, F376-F381 (2013)

  • [40]P. M. Zygmunt, J. Petersson, D. A. Andersson, H. Chuang, M. Sørgård, V. Di Marzo, D. Julius and E. D. Högestätt: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452-457 (1999)

  • [41]Y. Zhu and D. H. Wang: Segmental regulation of sodium and water excretion by TRPV1 activation in the kidney. J Cardiovasc Pharmacol, 51, 437-442 (2008)

  • [42]F. Gao, D. Sui, R. M. Garavito, R. M. Worden and D. H. Wang: Salt intake augments hypotensive effects of transient receptor potential vanilloid 4: functional significance and implication. Hypertension, 53, 228-235 (2009)

  • [43]D. F. Woodward, Y. Liang and A. H. Krauss: Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol, 153, 410-419 (2008)

  • [44]C. S. Spada, A. H. Krauss, D. F. Woodward, J. Chen, C. E. Protzman, A. L. Nieves, L. A. Wheeler, D. F. Scott and G. Sachs: Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp Eye Res, 80, 135-145 (2005)

  • [45]Y. Koura, A. Ichihara, Y. Tada, Y. Kaneshiro, H. Okada, C. J. Temm, M. Hayashi and T. Saruta: Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys. J Am Soc Nephrol, 15, 1488-1494 (2004)

  • [46]D. L. Mattson: Importance of the renal medullary circulation in the control of sodium excretion and blood pressure. Am J Physiol Regul Integr Comp Physiol, 284, R13-R27 (2003)

  • [47]J. Li and D. H. Wang: Differential mechanisms mediating depressor and diuretic effects of anandamide. J Hypertens, 24, 2271-2276 (2006)

  • [48]R. D. Sofia, L. C. Knobloch, J. J. Harakal and D. J. Erikson: Comparative diuretic activity of delta9-tetrahydrocannabinol, cannabidiol, cannabinol and hydrochlorothiazide in the rat. Arch Int Pharmacodyn Ther, 225, 77-87 (1977)

  • [49]C. A. Paronis, G. A. Thakur, S. Bajaj, S. P. Nikas, V. K. Vemuri, A. Makriyannis and J. Bergman: Diuretic effects of cannabinoids. J Pharmacol Exp Ther, 344, 8-14 (2013)

  • [50]E. J. Ishac, L. Jiang, K. D. Lake, K. Varga, M. E. Abood and G. Kunos: Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol, 118, 2023-2028 (1996)

  • [51]K. Varga, K. D. Lake, D. Huangfu, P. G. Guyenet and G. Kunos: Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension, 28, 682-686 (1996)

  • [52]K. D. Lake, B. R. Martin, G. Kunos and K. Varga: Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension, 29, 1204-1210 (1997)

  • [53]K. Varga, K. Lake, B. R. Martin and G. Kunos: Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol, 278, 279-283 (1995)

  • [54]G. Godlewski, S. O. Alapafuja, S. Batkai, S. P. Nikas, R. Cinar, L. Offertaler, D. Osei-Hyiaman, J. Liu, B. Mukhopadhyay, J. Harvey-White, J. Tam, K. Pacak, J. L. Blankman, B. F. Cravatt, A. Makriyannis and G. Kunos: Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol, 17, 1256-1266 (2010)

  • [55]K. D. Lake, D. R. Compton, K. Varga, B. R. Martin and G. Kunos: Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther, 281, 1030-1037 (1997)

  • [56]S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, L. Offertaler, K. Mackie, M. A. Rudd, R. D. Bukoski and G. Kunos: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation, 110, 1996-2002 (2004)

  • [57]E. E. Muirhead: The medullipin system of blood pressure control. Am J Hypertens, 4, 556s-568s (1991)

  • [58]E. E. Muirhead: Renal vasodepressor mechanisms: the medullipin system. J Hypertens Suppl, 11, S53-S58 (1993)

  • [59]G. Bergstrom, G. Gothberg, G. Karlstrom and J. Rudenstam: Renal medullary blood flow and renal medullary antihypertensive mechanisms. Clin Exp Hypertens, 20, 1-26 (1998)

  • [60]D. T. Brozoski, C. Dean, F. A. Hopp and J. L. Seagard: Uptake blockade of endocannabinoids in the NTS modulates baroreflex-evoked sympathoinhibition. Brain Res, 1059, 197-202 (2005)

  • [61]J. E. Schlosburg, S. G. Kinsey and A. H. Lichtman: Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J, 11, 39-44 (2009)

  • [62]B. F. Cravatt, A. Saghatelian, E. G. Hawkins, A. B. Clement, M. H. Bracey and A. H. Lichtman: Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A, 101, 10821-10826 (2004)

  • [63]M. Karsak, E. Gaffal, R. Date, L. Wang-Eckhardt, J. Rehnelt, S. Petrosino, K. Starowicz, R. Steuder, E. Schlicker, B. Cravatt, R. Mechoulam, R. Buettner, S. Werner, V. Di Marzo, T. Tüting and A. Zimmer: Attenuation of allergic contact dermatitis through the endocannabinoid system. Science, 316, 1494-1497 (2007)

  • [64]F. Massa, G. Marsicano, H. Hermann, A. Cannich, K. Monory, B. F. Cravatt, G. L. Ferri, A. Sibaev, M. Storr and B. Lutz: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest, 113, 1202-1209 (2004)

  • [65]A. Jayamanne, R. Greenwood, V. A. Mitchell, S. Aslan, D. Piomelli and C. W. Vaughan: Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol, 147, 281-288 (2006)

  • [66]P. Janiak, B. Poirier, J. P. Bidouard, C. Cadrouvele, F. Pierre, L. Gouraud, I. Barbosa, J. Dedio, J. P. Maffrand, G. Le Fur, S. O’Connor and J. M. Herbert: Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int, 72, 1345-1357 (2007)

  • [67]B. Poirier, J. P. Bidouard, C. Cadrouvele, X. Marniquet, B. Staels, S. E. O’Connor, P. Janiak and J. M. Herbert: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab, 7, 65-72 (2005)

  • [68]M. Gary-Bobo, G. Elachouri, J. F. Gallas, P. Janiak, P. Marini, C. Ravinet-Trillou, M. Chabbert, N. Cruccioli, C. Pfersdorff, C. Roque, M. Arnone, T. Croci, P. Soubrié, F. Oury-Donat, J. P. Maffrand, B. Scatton, F. Lacheretz, G. Le Fur, J. M. Herbert and M. Bensaid: Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology, 46, 122-129 (2007)

  • [69]F. Barutta, A. Corbelli, R. Mastrocola, R. Gambino, V. Di Marzo, S. Pinach, M. P. Rastaldi, P. C. Perin and G. Gruden: Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes, 59, 1046-1054 (2010)

  • [70]F. Yi, M. Xia, N. Li, C. Zhang, L. Tang and P. L. Li: Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats. Hypertension, 53, 90-96 (2009)

  • [71]F. Yi, A. Y. Zhang, J. L. Janscha, P. L. Li and A. P. Zou: Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int, 66, 1977-1987 (2004)

  • [72]H. Han, Y. Wang, X. Li, P. A. Wang, X. Wei, W. Liang, G. Ding, X. Yu, C. Bao, Y. Zhang, Z. Wang and F. Yi: Novel role of NOD2 in mediating Ca2+ signaling: evidence from NOD2-regulated podocyte TRPC6 channels in hyperhomocysteinemia. Hypertension, 62, 506-511 (2013)

  • [73]F. Yi, E. A. dos Santos, M. Xia, Q. Z. Chen, P. L. Li and N. Li: Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats. Am J Nephrol, 27, 262-268 (2007)

  • [74]M. Xia, G. Li, J. M. Abais, K. Boini, P.-L. Li and J. K. Ritter: Protective action of prostamide E2 on hyperhomocysteinemia-induced NLRP3 inflammasome activation and prodocyte injury Submitted (2015)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review

Anandamide and its metabolites: what are their roles in the kidney?

Joseph K. Ritter 1,*, Guangbi Li 1, Min Xia 1, Krishna Boini 1
Affiliation
Article Info

1 Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Box 980613, 1217 E. Marshall Street, Richmond, VA

*Author to whom correspondence should be addressed.

 

Abstract

Anandamide (AEA) is the N-acyl ethanolamide of arachidonic acid, an agonist of cannabinoid and non-cannabinoid receptors in the body. The kidneys are enriched in AEA and in enzymes that metabolize AEA, but the roles of AEA and its metabolites in the kidney remain poorly understood. This system likely is involved in the regulation of renal blood flow and hemodynamics and of tubular sodium and fluid reabsorption. It may act as a neuromodulator of the renal sympathetic nervous system. AEA and its cyclooxygenase-2 metabolites, the prostamides, in the renal medulla may represent a unique antihypertensive system involved in the long-term control of blood pressure. AEA and its metabolites are also implicated as modulators of inflammation and mediators of signaling in inflammation. AEA and its metabolites may be influential in chronic kidney disease states associated with inflammation and cardiovascular diseases associated with hyperhomocysteinemia. The current knowledge of the roles of AEA and its derivatives highlights the need for further research to define and potentially exploit the role of this endocannabinoid system in the kidney.

Keywords

  • Anandamide
  • Endocannabinoid
  • Prostamide
  • Kidney
  • Review

References